iShares Currency Hedged MSCI EAFE ETF (BATS: HEFA)

에 대한 최신 뉴스 iShares Currency Hedged MSCI EAFE ETF (BATS:HEFA)

iShares Currency Hedged MSCI EAFE ETF

Financial Services

Industrials

Healthcare

Consumer Cyclical

Consumer Defensive

Technology

Basic Materials

Communication Services

Utilities

Energy

Real Estate

The fund generally will invest at least 90% of its assets in the component securities (including indirect investments through the underlying fund) and other instruments of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is composed of large- and mid-capitalization equities in Europe, Australasia, and the Far East while mitigating exposure to fluctuations between the value of the component currencies and the U.S. dollar.

Ishares Msci Eafe ETF

Blackrock Cash Funds: Treasury, Sl Agency Shares

Chase Freedom Unlimited®

Currency ETFs

ETFs

GOOGL

HEFA

USDU

PowerShares DB US Dollar Index Bullish Fund

미국 달러의 추세는 강세를 보이고 있지만 Invesco DB US Dollar Index Bullish Fund (NYSE:UUP)는 올해 들어 약 0.8% 하락했다. 여러 지표들이 달러가 단기적으로도 회복세를 유지할 수 있음을 시사하고 있으며, 이 추세로 혜택을 받을 수 있는 여러 ETF들이 있다:

그린백에 베팅하기: 달러 궤적은 여전히 강하며, 이 ETF들이 큰 승리를 거둘 것으로 전망

Active Ingredient Manufacturing Transfer to the U.S. Complete&nbsp;
PRINCETON, N.J., July 1, 2025 /PRNewswire/ --&nbsp;Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active ingredient under its partnership agreement with Sterling Pharma Solutions (Sterling). The transfer from Europe to the United States (U.S.) included the optimization and implementation of a commercially viable, scalable production process for this important active ingredient, which is used in the topical drug product formulations <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=193312477&amp;u=https%3A%2F%2Fwww.hybryte.com%2F&amp;a=HyBryte%E2%84%A2">HyBryte&#x2122;</a> and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=1271944488&amp;u=https%3A%2F%2Fwww.soligenix.com%2Fpipeline-programs%2Fsgx302-for-mild-to-moderate-psoriasis%2F&amp;a=SGX302">SGX302</a> being developed for the treatment of cutaneous T-cell lymphoma (CTCL) and psoriasis, respectively. Synthetic hypericin is a potent photosensitizer that is topically applied to skin lesions. Soligenix and Sterling have enabled cGMP (current good manufacturing practice) manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.

News

SNGX

Soligenix Transfers Manufacturing Process For Synthetic Hypericin Active Ingredient Under Partnership Agreement With Sterling Pharma Solutions

Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that result in blindness. This worldwide, non-exclusive license is pursuant to the agreement between Abeona and Beacon, announced in July 2024, to evaluate the therapeutic potential of AAV204.
AAV204, a novel AAV capsid from the AIM&#x2122; capsid library licensed by Abeona from the University of North Carolina at Chapel Hill, has been shown to achieve high macular and optic nerve transduction levels after para-retinal administration and has also been shown to facilitate transduction of both the inner and outer retina after intravitreal administration in mice and non-human primates.
"Beacon's option exercise further validates AAV204's potential to enable targeted delivery of gene therapies in rare and prevalent ophthalmic diseases," said Dr. Madhav Vasanthavada, Chief Commercial Officer and Head of Business Development at Abeona Therapeutics. "Our non-exclusive agreement with Beacon enables us to fully explore the therapeutic value of AAV204 in additional ophthalmic diseases."
The exercise of this license option concludes Beacon's initial evaluation of the AAV204 capsid for development and commercialization of gene therapies and gives Beacon the right to use AAV204 in connection with up to five gene or ophthalmology disease targets. Under the terms of the agreement, Abeona will receive an undisclosed upfront license payment with additional payments upon the achievement of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating AAV204.

Biotech

General

ABEO

Abeona Therapeutics Announces It Has Exercised Its Option To License Abeona's Patented Aav204 Capsid For Use In Potential Gene Therapies

Financing

LITM

Snow Lake To Invest AUD$1.4M In GTi Energy's AUD$4.5M Eqiuty Financing To Support Advancement Of Its Lo Herma ISR Amenable Uranium Project

&nbsp;Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active ingredient under its partnership agreement with Sterling Pharma Solutions (Sterling). The transfer from Europe to the United States (U.S.) included the optimization and implementation of a commercially viable, scalable production process for this important active ingredient, which is used in the topical drug product formulations <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=193312477&amp;u=https%3A%2F%2Fwww.hybryte.com%2F&amp;a=HyBryte%E2%84%A2">HyBryte&#x2122;</a> and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=1271944488&amp;u=https%3A%2F%2Fwww.soligenix.com%2Fpipeline-programs%2Fsgx302-for-mild-to-moderate-psoriasis%2F&amp;a=SGX302">SGX302</a> being developed for the treatment of cutaneous T-cell lymphoma (CTCL) and psoriasis, respectively. Synthetic hypericin is a potent photosensitizer that is topically applied to skin lesions. Soligenix and Sterling have enabled cGMP (current good manufacturing practice) manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.

Soligenix Announces That is Successfully Manufactured Synthetic Hypericin At Sterling Pharma Solutions

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Adaptive's clonoSEQ&#xAE; test for measurable residual disease (MRD) assessment in lymphoid malignancies into OncoEMR&#xAE;, Flatiron's cloud-based Electronic Medical Record (EMR) platform.
Integrating clonoSEQ within OncoEMR simplifies and accelerates access to MRD testing to over 4,500 clinicians across the Flatiron network of 1,000 community-based cancer care locations in the U.S. This integration enables providers to order and review clonoSEQ MRD testing results directly within the EMR, leading to more efficient testing workflows and increasing real-time insights into the patient's disease status.
This integration will be effective as of today, July 1, 2025, to all OncoEMR's MPI users. clonoSEQ will continue to be available to providers outside the Flatiron network through a rapidly expanding number of other EMR integrations and via Adaptive's online diagnostic portal.
 &nbsp;

ADPT

Adaptive Biotechnologies Integrates Adaptive's clonosSEQ Test For MRD Assessment In Lymphoid Malignancies Into OncoEMR, Flatiron's Cloud-Based EMR Platform

CGTX

Cognition Therapeutics Study Of Zervimesine (CT1812) For Early Alzheimer's Disease Surpasses 50% Enrollment Target

AMC Enters Transaction Support Agreement With Creditor Groups; Includes ~$223.3M Of New Money Financing, Immediate Conversion Of $143.0M Of 6.00%/8.00% Senior Secured Exchangeable Notes due 2030 And Resolution Of Litigation With Certain Holders Of 7.5% Senior Secured Notes due 2029

Canaccord Genuity analyst Richard Close initiates coverage on Omada Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) with a Buy rating and announces Price Target of $27.

Price Target

Initiation

Analyst Ratings

OMDA

Canaccord Genuity Initiates Coverage On Omada Health with Buy Rating, Announces Price Target of $27

QMCO: -15% &#x7C; <a href="https://www.benzinga.com//node/46181747">Quantum shares are trading lower after the company delayed its FY25 10-K filing due to an ongoing review of its accounting.</a>
&nbsp;
CLRO: 140% &#x7C; <a href="https://www.benzinga.com//node/46182384">ClearOne Declares One-Time Special Stock Dividend On The Co's Issued And Outstanding Shares Of Common Stock And Any Common Stock Equivalents With Dividend Rights To Legacy Stockholders With A 100% Stake In The Proceeds From Any Eventual Sale Of All Or Substantially All Of The Co's Current Assets And Operations In One Or More Transactions</a>
&nbsp;
GPUS: 117% &#x7C; <a href="https://www.benzinga.com//node/46190175">Hyperscale Data's Ault Markets Plans To Launch Decentralized Cryptocurrency Exchange To Be Based In US, With Headquarters In Las Vegas, Nevada</a>

Movers

Trading Ideas

CLRO

GPUS

QMCO

Market-Moving News for July 1st

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering of $100 million of shares of its common stock. Nektar is selling 4,255,320 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $23.50 per share. The gross proceeds to Nektar from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Nektar has granted the underwriters a 30-day option to purchase up to an additional 638,298 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.&nbsp;All of the securities being sold in this offering are being offered by Nektar. The offering is expected to close on July 2, 2025, subject to the satisfaction of customary conditions.
Nektar intends to use the net proceeds from the offering for general corporate purposes, which may include research and development, clinical development and manufacturing costs to support the advancement of its drug candidates, as well as other general corporate purposes.
 &nbsp;

Offerings

NKTR

Nektar Therapeutics Prices Underwritten Public Offering Of $100M Of Shares At $23.50/Shr

Nouveau Monde Graphite Pays Q2 2025 Accrued Interest To Investissement Québec via Share Issuance

UK's CMA Considering Whether Global Payments / Worldpay Merger Will Reduce Competition Within Any Market

Pursuant to the Agreement and subject to the completion of certain closing procedures, the investor has agreed to exchange approximately $28 million in outstanding Senior Notes, consisting of $8 million in December 2026 notes, $2 million in January 2028 notes, and $18 million in August 2028 notes, for $13 million in newly issued 8.00% Senior Secured Second Lien Notes due January 1, 2028 (the "Notes"). In addition, the Company is issuing to the investor warrants to purchase an aggregate of approximately 52,000 common shares at an exercise price of&nbsp;$10.00&nbsp;per share. The warrants are exercisable for a period of seven years from the issuance date.

RILY

B. Riley Financial Reduces Total Outstanding Debt by ~$15M Through Private Bond Exchange Agreement

Ark Invest, a leading investment management firm led by Cathie Wood, has highlighted a pivotal development set to bridge the world of blockchain-based capital with the substantial U.S. mortgage market.
What Happened: According to Nick Grous, an associate portfolio manager at Ark Invest, the recent directive from the Federal Housing Finance Agency (FHFA) instructing Fannie Mae (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FNMA#OTC">FNMA</a>) and Freddie Mac (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FMCC#OTC">FMCC</a>) to consider cryptocurrency holdings, such as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), for mortgage loan risk assessments marks &#8220;crypto's first step into U.S. housing: from wallets to mortgages.&#8221;
&#8220;This directive introduces a novel bridge between blockchain-based capital and the $12 trillion U.S. mortgage market,&#8221; Grous notes.
Looking at the potential scale, Grous references iEmergent's 2024 Home Mortgage Disclosure Act (HMDA) data, which reported around &#8220;6 million mortgage originations in the U.S. last year, valued at $1.82 trillion.&#8221;
Based on an average loan size of approximately &#8220;$340,000,&#8221; Ark Invest&#8217;s analysis suggests that &#8220;if just 5% of mortgage borrowers included crypto-based assets in their applications, ~305,000 would qualify for a mortgage in this new framework—supporting $100 billion in originations.&#8221;
He further projects that &#8220;each additional percentage point of adoption would increase mortgage loan volume by ~$20 billion.&#8221;
This regulatory development, according to Ark Invest, &#8220;aligns with ARK's thesis that crypto will reshape legacy financial systems with greater transparency, automation, and interoperability.&#8221;
See Also: <a href="https://www.benzinga.com/crypto/25/06/46089173/michael-saylor-offers-btc-credit-model-as-bill-pulte-pushes-crypto-for-fannie-mae-freddie-mac-could-bitcoin-soon-count-toward-mortgage-qualification">Michael Saylor Offers BTC Credit Model As Bill Pulte Pushes Crypto For Fannie Mae, Freddie Mac: Could Bitcoin Soon Count Toward Mortgage Qualification? </a>
Why It Matters: The FHFA&#8217;s directive, issued last week, represents a significant shift.
It allows for the inclusion of cryptocurrency holdings, specifically &#8220;only those held on U.S.-regulated centralized exchanges,&#8221; as assets in single-family mortgage loan risk assessments.
Crucially, this directive &#8220;does not require converting crypto to U.S. dollars and does not include crypto held in self-custodied wallets.&#8221;
It also mandates &#8220;risk controls, like accounting for crypto market volatility and limiting how much crypto can count toward reserves,&#8221; signaling a cautious yet forward-looking approach to integration.
Last week, Strategy Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) Michael Saylor stepped forward to offer Strategy&#8217;s (formerly MicroStrategy) <a href="http://46089173/michael-saylor-offers-btc-credit-model-as-bill-pulte-pushes-crypto-for-fannie-mae-freddie-mac-could-bitcoin-soon-count-toward-mortgage-qualification">Bitcoin Credit Model</a> to support the initiative. 
Meanwhile, the Bitcoin Policy Institute <a href="https://www.btcpolicy.org/articles/the-powerful-fannie-mae-policy-change-to-unlock-bitcoin-based-mortgages">hails</a> this as a potential game-changer, stating that a tweak to Fannie Mae&#8217;s Selling Guide to recognize Bitcoin as collateral could unlock homeownership for millions, aligning with Donald Trump&#8217;s vision to make the U.S. the &#8220;Bitcoin Capital of the planet.&#8221;
Price Action: Fannie Mae shares ended 1.95% lower on Monday. It has risen by 177.33% on a year-to-date basis and 553.42% over the past year.
On the other hand, Freddie Mac declined 1.55% on Monday, and it has risen by 144.51% on a year-to-date basis and 505.88% over the past year.
After hitting fresh records on Friday and Monday, on Tuesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket. The SPY was down 0.18% at $616.74, while the QQQ declined 0.26% to $550.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46189081/what-are-stock-tokens-and-how-to-trade-them-robinhoods-new-offering-merges-owning-stocks-with-blockchain-tech-heres-how-it-works">What Are Stock Tokens And How To Trade Them? Robinhood&#8217;s New Offering Merges Owning Stocks With Blockchain Tech: Here&#8217;s How It Works</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Image Via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

$ETH

FMCC

FNMA

MSTR

Bitcoin, Ethereum Could Soon Help You Get A Mortgage Now — Cathie Wood's Ark Invest Sees $12 Trillion Opportunity After FHFA Move

Cash proceeds will be allocated to debt repayment, resulting in a pro-forma leverage ratio below 2.0x after the closing, to be further reduced with the previously announced planned divestiture of Greif's timberland business. These actions will enable future disciplined capital redeployment and optionality for strategic growth investments.
Strategic Rationale:
<ul>
<li>Further Positions Greif as a Packaging Leader</li>
<li>Allows Greif to Deliver More Durable Earnings</li>
<li>Enhances Capital Utilization, Reducing Recurring Capital Needs</li>
<li>Enables Debt Reduction, Unlocking Value-Creation Opportunities</li>
</ul>

Greif To Sell Containerboard Unit And CorrChoice Network To Packaging Corporation Of America For $1.8B

YY Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) ("YY Group," "YYGH," or the "Company"), a global leader in on-demand workforce solutions and integrated facility management (IFM), is pleased to announce its acquisition of Pesticide Pest Control Pte. Ltd., a Singapore-based pest control company with over 30 years of operational history.
The company will be rebranded as Pest Fighter Management Pte. Ltd., marking the beginning of its next growth phase under YY Group's integrated IFM platform. The acquisition is expected to close on July 1, 2025.
Revenue Trajectory and Outlook
YY Group's integration of Pest Fighter is expected to contribute significantly to its growth trajectory. The Group projects annual revenue to increase from S$26.3 million in 2023 to S$96.0 million by 2028, representing a compound annual growth rate of 29.1% substantially outpacing industry averages of 5% to 8% annually.
Pest Fighter is anticipated to enhance client retention, strengthen the value of bundled services, and improve profit margins, further anchoring YY Group's ability to deliver comprehensive facility solutions.

YYGH

YY Group Acquires Pesticide Pest Control For Undisclosed Terms; Co To Be Rebranded As Pest Fighter Management Pte. Ltd.

Greif To Sell Containerboard Business to Packaging Corp. for $1.8B in All-Cash Deal; Proceeds to Cut Debt, Sharpen Portfolio Focus

NIP Group Inc. ("NIPG" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>), a leading digital entertainment company, today announced it has entered into a definitive asset-purchase agreement (the "Agreement") to acquire on-rack crypto mining machines (the "Products") from Fortune Peak Limited and Apex Cyber Capital Limited (together, the "Sellers"). These Products are currently used for Bitcoin mining and are expected to begin generating significant Bitcoin mining revenue for the Company upon closing of the acquisition. To support this initiative, NIPG has established a dedicated Digital Computing Division to manage the operations of the acquired Products and lead the future development of the Company's compute infrastructure capabilities. Importantly, this transaction marks a strategic extension of NIPG's business into the digital infrastructure space.
The Products, consisting of data center capacity with a combined hash rate of 3.11 EH/s, are currently utilized for Bitcoin mining operations with expected production of approximately 60 Bitcoins per month, and will continue operating immediately after closing of the proposed transaction. Under the terms of the Agreement, NIPG will pay the consideration for the Products through issuance of approximately 119,553,439 Class A ordinary shares of the Company to the Sellers. In connection with the consummation of the proposed transactions contemplated by the Agreement, the Company and the Sellers will also enter into an investor rights agreement to define certain rights and obligations among them with respect to the Company.
The closing of the proposed transaction is expected to occur on or before September 30, 2025, and is subject to customary closing conditions. There can be no assurance that the closing conditions will be satisfied nor that the proposed transaction will be completed before that date or at all.

NIPG

NIP Group to Acquire Bitcoin Mining Machines, Expands Into Digital Infrastructure

Rosenblatt analyst Kevin Cassidy maintains Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) with a Neutral and maintains $3 price target.

BZAI

Rosenblatt Maintains Neutral on Blaize Holdings, Maintains $3 Price Target

Investar Holding Corporation ("Investar") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISTR#NASDAQ">ISTR</a>), the holding company for Investar Bank, N.A., and Wichita Falls Bancshares, Inc. ("Wichita Falls"), the holding company for First National Bank, Wichita Falls, Texas, jointly announced today that they have entered into a definitive agreement pursuant to which Investar will acquire Wichita Falls for cash and stock consideration. In connection with the proposed acquisition, Investar also announced today a private placement of $32.5 million of its newly designated 6.5% Series A Non-Cumulative Perpetual Convertible Preferred Stock.
The definitive agreement has been unanimously approved by the boards of directors of Investar and Wichita Falls, and the closing of the transaction, which is expected to occur in the fourth quarter of 2025, is subject to customary conditions, including shareholder and regulatory approvals. The definitive agreement provides that upon the closing of the transaction, Wichita Falls shareholders will be entitled to receive an aggregate of 3,955,334 shares of Investar common stock, and cash consideration of $7.2 million, in exchange for their shares, subject to adjustment under certain circumstances. Based on the closing price of $19.32 for Investar common stock on June 30, 2025, the transaction would result in aggregate consideration of approximately $83.6 million, or $134.67 per share of Wichita Falls common stock.
&nbsp;

ISTR

Investar Holding Corporation Announced Merger with Wichita Falls Bancshares

미국 달러의 추세는 강세를 보이고 있지만 Invesco DB US Dollar Index Bullish Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>)는 올해 들어 약 0.8% 하락했다.
여러 지표들이 달러가 단기적으로도 회복세를 유지할 수 있음을 시사하고 있으며, 이 추세로 혜택을 받을 수 있는 여러 <a href="https://www.benzinga.com/etfs">ETF</a>들이 있다:
<ul>
<li>WisdomTree Bloomberg U.S. Dollar Bullish Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USDU#NYSE">USDU</a>): 이 액티브 관리 ETF는 블룸버그 달러 총 수익 지수를 추적하며, 미국 달러에 직접적인 노출을 제공한다. 이 ETF는 국제 주식 및 채권과 강한 음의 상관관계를 가지므로, 글로벌 시장 불안정성에 대한 좋은 헤지 수단이 된다. 운용 수수료는 0.5%이다.</li>
</ul>
<ul>
<li>iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>): 강한 달러는 국내 중심의 소형주 기업들에게 유리하게 작용하는 경향이 있다. 이는 이들 기업들이 국제 무역으로 인한 환율 변동에 덜 영향을 받기 때문이다. 이 ETF는 러셀 2000 지수를 추적하고 운용 수수료는 0.19%이다.</li>
</ul>
<ul>
<li>iShares Currency Hedged MSCI EAFE ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/HEFA#BATS">HEFA</a>): 달러가 강세를 보일 때, 투자자들은 통화 헤지된 국제 펀드로 눈을 돌릴 수 있다. HEFA는 유럽, 아시아 태평양 및 동아시아의 선진 시장에 대한 노출을 제공하면서 환위험을 완화한다. 운용 수수료는 0.38%다.</li>
</ul>
<h3 class="wp-block-heading">달러에 영향을 미치는 시장 요인들</h3>
도널드 트럼프 대통령의 최신 관세 부과 조치는 글로벌 무역 긴장을 재점화시켜 일반적으로 달러에 긍정적인 영향을 미치는 시장 불확실성을 야기했다. 1월 30일, 트럼프는 멕시코와 캐나다에 25% 관세 부과(현재는 연기됨) 및 2월 4일 발효되는 모든 중국 수입품에 10% 관세 부과를 포함한 새로운 관세를 발표했다.
중국은 미국 상품에 대한 목표 관세를 부과하고 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)과 같은 기업들에게 잠재적 제재에 대한 경고를 발했다. 캐나다도 미국에 대한 <a href="https://www.benzinga.com/markets/25/02/43423087/canada-retaliates-against-trumps-tariffs-with-countermeasures-25-tariffs-on-107-billion-of-us-made-goods">보복 관세를 부과</a>했다. 이러한 무역 정책에서 발생하는 불확실성은 투자자들이 안전 자산을 찾게 하여 달러에 대한 수요를 증가시키고 있다.
또한 읽기: <a href="https://kr.benzinga.com/news/usa/economy/%ED%8A%B8%EB%9F%BC%ED%94%84-%EC%9D%B4%EB%9E%80%EC%97%90-%EC%B5%9C%EB%8C%80-%EA%B2%BD%EC%A0%9C%EC%A0%81-%EC%95%95%EB%B0%95-%EC%A4%91%EA%B5%AD-%EA%B4%80%EC%84%B8-%EB%B3%B4%EB%B3%B5-%EA%B4%9C/" target="_blank" rel="noopener">트럼프, 이란에 대한 최대 경제적 압박 확인 및 중국의 관세 보복 &#8216;괜찮다&#8217; 발언</a>
연방준비제도는 1월 회의에서 금리를 4.25%–4.5%로 동결하며 인플레이션 우려가 남아 있는 상황에서 신중한 접근을 강조했다. 금리 인하에 대한 즉각적인 계획이 없고, 관세가 수입세로 작용하여 여전히 인플레이션 압력이 우려되는 가운데, 연준은 금리를 더 오랫동안 높게 유지할 수 있다. 덜 비둘기적인 연준은 일반적으로 달러에 긍정적이다. 높은 금리는 미국 자산을 외국 투자자들에게 더 매력적으로 만든다.
한편, 노동 시장 데이터는 경제가 안정적인 기반을 유지하고 있음을 시사한다. 1월의 <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43559446/us-economy-adds-fewer-than-expected-jobs-in-january-yet-unemployment-rate-slows-wage-growth-spikes">일자리 증가가 약간 둔화되었지만</a>, 4.0%의 실업률은 여전히 낮다.
임금 증가가 계속 강세를 보이면서 소비자 지출을 지원하고 연준이 2025년 6월 이전에 금리를 서둘러 인하하지 않을 것이라는 기대를 강화하고 있다.
제프리 로치(Jeffrey Roach), LPL 파이낸셜의 수석 이코노미스트가 비즈니스 스탠다드의 보도에서 언급했듯이, &#8220;<a href="https://www.benzinga.com/news/econ-s/25/02/43565669/january-jobs-report-not-too-hot-not-too-cold-leaves-interest-rate-cuts-unlikely-expert" target="_blank" rel="noopener" data-google-interstitial="false">4%의 실업률</a>은 매우 낮게 평가되며, 연준이 단기적으로 기준 금리를 변경하지 않을 이유를 제공한다.&#8221;
<h3 class="wp-block-heading">달러의 단기 전망</h3>
스테이트 스트리트 글로벌 어드바이저스(State Street Global Advisors)는 <a href="https://www.ssga.com/us/en/intermediary/insights/currency-commentary-january-2025">미국 달러가 2025년 1분기까지 강세를 유지할 것으로 예상</a>하며, 이는 강력한 성장, 상승하는 수익률 및 무역 긴장 속에서의 안전 자산으로서의 매력에 기인한다.
그러나 강력한 4분기 랠리 이후 롱 달러 포지션이 과열되면서, 차익 실현으로 인한 다음 1~2개월 동안의 약한 조정이 가능성 있다.
느린 입법 과정은 트럼프의 성장 긍정적인 정책에 대한 낙관론을 약화시킬 수 있지만, 중대한 경제 둔화가 발생하지 않는 한, 달러의 하락은 일시적이고 얕을 것으로 예상된다.

다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/02/43560112/south-koreas-defense-sector-gets-a-us-gateway-with-kdef-etf">대한민국 방산 부문이 KDEF ETF를 통해 미국 시장에 진출</a></li>
</ul>
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

iShares Currency Hedged MSCI EAFE ETF

뉴스

에 대한 최신 뉴스 iShares Currency Hedged MSCI EAFE ETF (BATS:HEFA)

토요일, 2월 08, 2025

뉴스

파트너 / 기고자

벤징가 글로벌